See more : Ishizuka Glass Co., Ltd. (5204.T) Income Statement Analysis – Financial Results
Complete financial analysis of Biotricity, Inc. (BTCY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Biotricity, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Pan Asian Microvent Tech (Jiangsu) Corporation (688386.SS) Income Statement Analysis – Financial Results
- Doms Industries Limited (DOMS.NS) Income Statement Analysis – Financial Results
- Zimplats Holdings Limited (ZIM.AX) Income Statement Analysis – Financial Results
- Asahi Rubber Inc. (5162.T) Income Statement Analysis – Financial Results
- Kaori Heat Treatment Co., Ltd. (8996.TW) Income Statement Analysis – Financial Results
Biotricity, Inc. (BTCY)
About Biotricity, Inc.
Biotricity, Inc., a medical technology company, provides biometric data monitoring solutions primarily in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It offers Bioflux mobile cardiac telemetry solution, an integrated ECG device; and ECG analysis software that analyzes and synthesizes patient ECG monitoring data, as well as software components. The company is based in Redwood City, California.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 12.06M | 9.64M | 7.65M | 3.38M | 1.42M | 398.20K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 3.71M | 4.20M | 3.08M | 2.11M | 931.95K | 338.34K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 8.36M | 5.44M | 4.57M | 1.27M | 485.77K | 59.87K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 69.27% | 56.46% | 59.74% | 37.60% | 34.26% | 15.03% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 2.57M | 3.23M | 2.74M | 2.06M | 1.36M | 1.31M | 1.76M | 1.14M | 1.14M | 23.20K | 53.60K |
| General & Administrative | 14.61M | 17.62M | 18.56M | 12.57M | 10.05M | 7.34M | 5.96M | 4.80M | 3.99M | 56.09K | 29.25K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 14.61M | 17.62M | 18.56M | 12.57M | 10.05M | 7.34M | 5.96M | 4.80M | 3.99M | 56.09K | 29.25K |
| Other Expenses | 0.00 | -181.94K | -1.14M | -67.10K | 16.94K | 0.00 | 0.00 | 0.00 | 0.00 | -1.22K | -1.15K |
| Operating Expenses | 17.18M | 20.85M | 21.31M | 14.62M | 11.42M | 8.65M | 7.72M | 5.94M | 5.13M | 89.60K | 89.92K |
| Cost & Expenses | 20.89M | 25.05M | 24.39M | 16.74M | 12.35M | 8.99M | 7.72M | 5.94M | 5.13M | 89.60K | 89.92K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 5.19M | 2.58M | 10.57M | 2.48M | 92.42K | 0.00 | 879.42K | 1.18M | 59.88K | 0.00 | 0.00 |
| Depreciation & Amortization | 5.95K | 346.26K | 68.34K | 347.12K | 148.76K | 8.58M | 7.72M | 5.94M | 9.05K | 810.00 | 1.15K |
| EBITDA | -8.90M | -15.40M | -18.02M | -13.35M | -10.93M | -8.59M | 0.00 | -5.94M | -5.12M | 0.00 | -89.92K |
| EBITDA Ratio | -73.75% | -161.69% | -233.65% | -396.45% | -769.81% | -2,157.73% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -8.83M | -15.59M | -17.88M | -13.42M | -10.91M | -8.59M | -7.72M | -5.94M | -5.13M | -90.41K | -91.07K |
| Operating Income Ratio | -73.18% | -161.75% | -233.68% | -396.45% | -769.81% | -2,157.73% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -5.27M | -3.25M | -12.39M | -2.78M | -136.26K | 0.00 | -900.00K | -1.87M | -55.85K | 7.00 | 0.00 |
| Income Before Tax | -14.09M | -18.66M | -29.13M | -15.49M | -11.07M | -8.59M | -8.62M | -7.81M | -5.19M | -90.81K | -91.07K |
| Income Before Tax Ratio | -116.84% | -193.57% | -380.78% | -457.67% | -780.61% | -2,157.73% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 2.40M | 9.43M | 2.07M | -39.41K | -171.86K | -6.84M | -4.76M | 50.82K | -810.00 | -1.15K |
| Net Income | -14.09M | -18.66M | -29.13M | -15.49M | -11.07M | -8.59M | -8.62M | -7.81M | -5.19M | -90.81K | -91.07K |
| Net Income Ratio | -116.84% | -193.57% | -380.78% | -457.67% | -780.61% | -2,157.73% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.66 | -2.15 | -3.85 | -2.48 | -1.85 | -1.54 | -1.72 | -1.81 | -1.42 | -0.06 | -0.06 |
| EPS Diluted | -1.66 | -2.15 | -3.85 | -2.48 | -1.85 | -1.54 | -1.72 | -1.81 | -1.42 | -0.06 | -0.06 |
| Weighted Avg Shares Out | 8.99M | 8.66M | 7.57M | 6.25M | 5.99M | 5.56M | 5.03M | 4.31M | 3.64M | 1.50M | 1.50M |
| Weighted Avg Shares Out (Dil) | 8.99M | 8.66M | 7.57M | 6.25M | 5.99M | 5.56M | 5.03M | 4.31M | 3.64M | 1.50M | 1.50M |
Biotricity Prices $15 Million Underwritten Public Offering of Common Stock and Listing on the Nasdaq Capital Market
REDWOOD CITY, CA / ACCESSWIRE / August 26, 2021 / Biotricity, Inc. (OTCQB:BTCY), a medical diagnostic and consumer healthcare technology company, today announced the pricing of an underwritten public offering of 5,000,000 shares of common stock of the Company, at...
Biotricity Announces Proposed Underwritten Public Offering of Common Stock in Connection with Expected Nasdaq Listing
REDWOOD CITY, CA / ACCESSWIRE / August 25, 2021 / Biotricity, Inc. (OTCQB:BTCY), a medical diagnostic and consumer healthcare technology company, today announced that it intends to offer shares of its common stock for sale in an underwritten public offering....
Biotricity, Inc. (BTCY) CEO Waqaas Al-Siddiq on Q1 2022 Results - Earnings Call Transcript
Biotricity, Inc. (BTCY) CEO Waqaas Al-Siddiq on Q1 2022 Results - Earnings Call Transcript
Biotricity Reports 290% Revenue Growth Year Over Year in Record First Quarter
REDWOOD CITY, CA / ACCESSWIRE / August 16, 2021 / Biotricity, Inc. (OTCQB:BTCY), a medical diagnostic and consumer healthcare technology company, is pleased to provide financial results for its fiscal 2022 first quarter, which ended June 30, 2021. Full financial...
Biotricity to Report First Quarter Fiscal 2022 Financial Results on August 16, 2021
REDWOOD CITY, CA / ACCESSWIRE / August 12, 2021 / Biotricity, Inc. (OTCQB:BTCY), a medical diagnostic and consumer healthcare technology company, today announced that it will release its financial results for the first quarter of fiscal 2022, ended June 30,...
Innovative Company Biotricity is Providing Solutions for Chronic Diseases
A new study revealed that 44% of older millennials that will soon hit 40 suffer at least one chronic health condition that takes a toll, both financially and emotionally — an alarming number compared to previous generations Chronic care is...
7 Reddit Penny Stocks to Bet On if You Have $100 to Gamble
Reddit traders aren't just focused on short squeezes. Here are seven ultra-risky Reddit penny stocks that have caught their attention.
Biotricity Reports Record Quarterly and Annual Revenue for Fiscal 2021
For fiscal 2021, management is noting the following highlights: Q4 revenue of $1.2 million represented the 8th consecutive quarter of triple-digit YoY growth
Biotricity, Inc. (BTCY) CEO Waqaas Al-Siddiq on Q4 2021 Results - Earnings Call Transcript
Biotricity, Inc. (BTCY) CEO Waqaas Al-Siddiq on Q4 2021 Results - Earnings Call Transcript
Biotricity Reports Record Quarterly and Annual Revenue for Fiscal 2021
REDWOOD CITY, CA / ACCESSWIRE / June 15, 2021 / Biotricity, Inc. (OTCQB:BTCY), a medical diagnostic and consumer healthcare technology company, is pleased to provide unaudited, preliminary financial results for its fiscal 2021 fourth quarter and fiscal year, which ended...
Source: https://incomestatements.info
Category: Stock Reports